• Thomas G. DeLougheryEmail author


Hemophilia A and B—lack of factors VIII and IX, respectively—are the most common forms of hemophilia. This chapter reviews the pathogenesis of hemophilia, diagnosis, and treatment including the use of desmopressin and factor concentrates.


Hemophilia Factor VIII deficiency Factor IX deficiency Concentrates Factor inhibitors Desmopressin 

Suggested Reading

  1. Croteau SE. Evolving complexity in hemophilia management. Pediatr Clin N Am. 2018;65(3):407–25.CrossRefGoogle Scholar
  2. Dunn A. The long and short of it: using the new factor products. Hematology Am Soc Hematol Educ Program. 2015;2015:26–32.CrossRefGoogle Scholar
  3. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811–22.CrossRefGoogle Scholar
  4. Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood. 2019;133(5):399–406.CrossRefGoogle Scholar
  5. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.CrossRefGoogle Scholar
  6. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389–98.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology/Medical Oncology, Department of Medicine, Pathology, and PediatricsOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations